Abstracts tagged "Comorbidity"

Abstract Number: 211 • 2015 ACR/ARHP Annual Meeting
The Epidemiology of Gout: Marked Increase in Incidence and Comorbidities over 20 Years
Mohanad Elfishawi¹, Nour Zleik¹, Zoran Kvrgic¹, Clement J. Michet Jr.², Cynthia S. Crowson³, Eric L. Matteson⁴ and Tim Bongartz¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Several studies have suggested that the prevalence of gout has increased over recent years. The majority of this data has been derived from insurance…
Abstract Number: 374 • 2015 ACR/ARHP Annual Meeting
High Prevalence of Osteoporosis and Fractures Is Associated with Abdominal Adiposity and Decreased Muscular Strength in Primary Necrotizing Vasculitides
Karine Briot¹, Bertrand Dunogué², Alexis Regent³, Pascal Cohen², Alice Berezne², Sami Kolta¹, Xavier Puéchal², Claire Le Jeunne⁴, Luc Mouthon⁵, Christian Roux¹, Loïc Guillevin⁶ and Benjamin Terrier², ¹Rheumatology B Department, Hôpital Cochin, Paris, France, ²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ³Service de médecine interne, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ⁵Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ⁶Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Overall survival of primary necrotizing vasculitides, including ANCA-associated vasculitis (AAV) and polyarteritis nodosa (PAN), has greatly improved over the last 50 years. Because of…
Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Jeffrey D. Greenberg², Leslie Harrold³ and J. Lynn Palmer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Southborough, MA, ³Department of Medicine, UMass Memorial Medical Center, Worcester, MA, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
Abstract Number: 1418 • 2015 ACR/ARHP Annual Meeting
The Importance of Comorbidity in Understanding the 6-Month Trajectories of Pain and Function after Total Hip Arthroplasty
C. Allyson Jones¹, Gian S. Jhangri², Lauren A. Beaupre¹ and Maria E. Suarez-Almazor³, ¹Physical Therapy, University of Alberta, Edmonton, AB, Canada, ²School of Public Health, University of Alberta, Edmonton, AB, Canada, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Osteoarthritis (OA) is chronic condition associated with a number of other comorbidities which may affect the 6 month pattern of recovery of total hip…
Abstract Number: 1503 • 2015 ACR/ARHP Annual Meeting
A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Claire I. Daien¹, Amandine Tubery², Guilhem du Cailar³, Aurore Royanez⁴, Thibault Mura⁵, Marie-Christine Picot⁶, Rodolphe Bourret⁷, François Roubille⁸, Jean Bousquet⁹, Jacques Morel¹, Pierre Fesler³ and Bernard Combe¹⁰, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology and Pharmacology, Montpellier, France, ⁵CIC, Hopital Gui De Chauliac, Montpellier, France, ⁶DIM, Montpellier, France, ⁷Direction Teaching hospital, Montpellier, France, ⁸Cardiology, Montpellier, France, ⁹Pneumology, Montpellier, France, ¹⁰Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Patients with inflammatory rheumatisms especially rheumatoid arthritis (RA) have a greater risk of cardiovascular diseases (CVD), infections, chronic respiratory diseases (CRD) and osteoporosis. As…
Abstract Number: 2163 • 2015 ACR/ARHP Annual Meeting
Associations Between Sex Differences, Pain, Insomnia, and Depression in Older Adults with Osteoarthritis: A Cross-Sectional Study
Minhui Liu¹, Susan McCurry¹, Michael Vitiello², Basia Belza¹ and Michael Von Korff³, ¹University of Washington School of Nursing, Seattle, WA, ²Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, ³Group Health Research Institute, Seattle, WA
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis and affects nearly 30 million Americans. Chronic pain is the major symptom in OA and…
Abstract Number: 2114 • 2014 ACR/ARHP Annual Meeting
Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents – Colchicine, NSAID, and Corticosteroids
Alfonso Perez¹, Robert Jackson², Jiao Yang³, Aki Shiozawa⁴, Shawn Yu⁴, Yimin Qin¹, Huifang Liang⁵ and Hyon K. Choi⁶, ¹Global Clinical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²Global Medical Office, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ³Analytical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁴Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁵Pharmacovigilance, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁶Boston University School of Medicine, Boston, MA
Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents - Colchicine, NSAID, and CorticosteroidsBackground/Purpose: There is a remarkable, increasing disease burden of gout and its…
Abstract Number: 2054 • 2014 ACR/ARHP Annual Meeting
Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Follow-up Period: The Role of Specific Comorbidities
Joëlle van den Hoek¹, Leo D. Roorda², Hendriek C. Boshuizen³, Gerard J. Tijhuis⁴, Trudi van den Bos⁵ and Joost Dekker⁶, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Comorbidity in patients with Rheumatoid Arthritis (RA) is highly prevalent and plays an important role in determining RA related outcomes. Several studies have reported…
Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study
Helga Radner^1,2, Kazuki Yoshida^3,4, Ihsane Hmamouchi⁵, Maxime Dougados^6,7, Josef Smolen⁸ and Daniel H Solomon⁹, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁴Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Descartes University, Cochin Hospital, Paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁸Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Rheumatology, Brigham and Women's Hospital, Boston, MA
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
Abstract Number: 1771 • 2014 ACR/ARHP Annual Meeting
Arterial Thrombotic Events in Systemic Vasculitis
Alexander Tsoukas¹, Sasha Bernatsky², Lawrence Joseph³, David Buckeridge⁴, Patrick Belisle⁵ and Christian A. Pineau¹, ¹Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose To estimate the incidence rate of clinically apparent arterial thrombotic events and associated comorbidities in patients with primary systemic vasculitis. Methods Using large-cohort administrative…
Abstract Number: 1570 • 2014 ACR/ARHP Annual Meeting
Relationship Between Psoriatic Arthritis Severity, Duration, and Comorbidities
Stacy Tanner¹, Molly McFadden², Daniel Clegg³ and Jessica Walsh⁴, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Internal Medicine-Division of Epidemiology, University of Utah, SLC, UT, ³Division of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, ⁴Rheumatology Room 4B200 School of Medicine, University of Utah, Salt Lake City, UT
Background/Purpose People with psoriatic arthritis (PsA) have an increased risk for several comorbidities that negatively impact quality of life and survival. Defining the relationships between…
Abstract Number: 1279 • 2014 ACR/ARHP Annual Meeting
Pre-Operative Musculoskeletal Comorbidities Limit Improvement in Functional Outcomes and Hip Pain in Total Hip Arthroplasty Patients
Scott Pascal¹, David Ayers², Wenjun Li², Leslie Harrold³, Jeroan Allison⁴ and Patricia D. Franklin², ¹University of Massachusetts Medical School, Worcester, MA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ³Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA
Pre-Operative Musculoskeletal Comorbidities Limit Improvement In Functional Outcomes And Hip Pain In Total Hip Arthroplasty PatientsBackground/Purpose: Identifying clinical factors predictive of total hip arthroplasty…
Abstract Number: 1053 • 2014 ACR/ARHP Annual Meeting
Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis
Christopher Sparks¹, Aleena Abdullah², Steven Zhao³, Cristina Estrach³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Musculoskeletal biology1, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, University Hospital Aintree, Liverpool, United Kingdom
Background/Purpose Co-morbidity has been shown to increase length of hospital stay and mortality in hospitalised patients. However, in early rheumatoid arthritis (eRA) co-morbidity may confound…
Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, J. Chapnick⁴ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
Abstract Number: 2137 • 2013 ACR/ARHP Annual Meeting
Important Predictors Of Patient-Reported Outcomes After TKR and THR Are Not Included In Risk Models Based On Administrative Data
Patricia D. Franklin¹, Leslie R. Harrold², Wenjun Li¹, Jeroan Allison³, David Ayers¹ and Courtland Lewis⁴, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ⁴Hartford Hospital, Hartford, CT
Background/Purpose: Because total knee (TKR) and total hip (THR) replacement surgery is performed to relieve pain and improve physical function in patients with advanced arthritis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].